WO2005072623A1 - Dispositif hemostatique - Google Patents

Dispositif hemostatique Download PDF

Info

Publication number
WO2005072623A1
WO2005072623A1 PCT/DK2005/000064 DK2005000064W WO2005072623A1 WO 2005072623 A1 WO2005072623 A1 WO 2005072623A1 DK 2005000064 W DK2005000064 W DK 2005000064W WO 2005072623 A1 WO2005072623 A1 WO 2005072623A1
Authority
WO
WIPO (PCT)
Prior art keywords
medical device
agent
hollowed
providing
mechanical pressure
Prior art date
Application number
PCT/DK2005/000064
Other languages
English (en)
Inventor
Kristina Devantier
Søren HERN
Original Assignee
Ferrosan A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrosan A/S filed Critical Ferrosan A/S
Publication of WO2005072623A1 publication Critical patent/WO2005072623A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/12031—Type of occlusion complete occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136—Balloons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00292—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
    • A61B2017/00336—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means with a protective sleeve, e.g. retractable or slidable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/00884—Material properties enhancing wound closure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices

Definitions

  • a medical device for providing haemostasis through an expansible catheter so as to exert both mechanical pressure and provide chemical haemostasis allows for surgeons to provide ' haemostasis in the event of generalised bleeding over a large surface area or localised to tissue areas.
  • MCH microfibrillar collagen
  • WO 03/055531 discloses the injection of putty-like paste of gelatine in surgical procedures.
  • EP 0 584 959 discloses an endoscopic haemostatic agent delivery system for incremental and small delivery of a haemostatic agent.
  • the document outlines advantages of collagen paste over Endo-Avitene ® .
  • the system does not provide for static mechanical pressure applied to the site of bleeding.
  • US 6,368,300 (C.R. Bard) discloses an endoscopic haemostatic agent delivery system.
  • the device addresses problems relating to the delivery of particulate haemostatic agents and does not provide for static mechanical pressure to the site of bleeding.
  • WO 00/18301 discloses a system for use in percutaneous occlusion of puncture sites and tract. It does not provide for static mechanical pressure to the site of bleeding.
  • US 5,443,481 (Lee) teaches the closure of a puncture in a wall of a artery. The document discloses the use of an enlongated catheter into the artery for delivery of a haemostatic agent. The method includes the steps of withdrawing the cardiovascular catheter from the artery while ensuring that the location of the puncture remains identified, and introducing a thrombogenic, hemostatic material so as to contact the wall of the artery at the puncture location, enabling the material to precipitate clot formation and seal the puncture.
  • a first aspect of the invention relates to a method of providing haemostatis and corresponding medical device comprising : a means for providing static mechanical pressure on a tissue area; and means for delivering an agent to the area.
  • the inventors have developed a method of providing haemostatis and corresponding medical device comprising: a means for providing static mechanical pressure on a tissue, venal or arterial area; and a means for delivering an agent to the area; wherein the delivering of the agent is by means of an outlet from a hollowed member, said hollowed member having a cross-sectional area wherein the means for providing the static mechanical pressure is suitable for exerting said mechanical pressure over a surface area of at least twice that of the cross-sectional area of the hollow member.
  • the invention is directed to a method of providing haemostatis and corresponding medical device comprising: a means for providing static mechanical pressure on a tissue venal or arterial area, said means being an expansible means so as to provide said pressure on the area; and a means for delivering an agent to the area.
  • a further aspect of the invention relates to a kit comprising the medical device as defined herein, a haemostatic agent, and a delivery system, such as a syringe and plunger or penlike delivery system as described herein.
  • mechanical pressure and "static mechanical pressure” is used interchangeably and intended to differentiate the pressure of the invention from that applied dynamically such as from a constant flow of gas or fluid or from manual pressure di rectly applied using a part of the human anatomy.
  • mechanical pressure relates to pressure in a constant but variable level applied by a mechanical object.
  • tissue is intended to mean all tissue and organs of the human or animal body. The term does not include veins and arteries themselves.
  • veins and arteries themselves.
  • veins and arteries themselves.
  • veins and arteries themselves.
  • veins and arteries themselves.
  • veins and arteries themselves.
  • veins and arteries themselves.
  • veins and arteries themselves.
  • veins and arteries themselves.
  • veins and arteries themselves.
  • a first aspect of the invention relates to a medical device comprising a means for providing static mechanical pressure on a tissue area; and a means for delivering an agent to the area.
  • haemostasis is provided by two separate means, acting in concert, either simultaneously or sequentially during the surgical procedure, by providing pressure on the site and by applying a haemostatic agent.
  • the invention allows for mechanical pressure to be applied to a tissue area distally removed from the surface of the wound area, such as into the body cavity.
  • the invention allows for the application of both a haemostatic agent and mechanical pressure to be applied to a tissue area distally removed from the surface.
  • the invention is also applicable to both means of haemostasis to be provided at the surface of the wound area.
  • the invention is also suitable for application of mechanical pressure to a tissue area distally removed from the surface and a haemostatic agent to the surface of the wound area such as, for instance, the mechanical pressure providing some degree of haemostasis, yet nonetheless resulting blood surfacing or bleeding which is then treated with the haemostatic agent.
  • the invention is directed to provide haemostasis to bleedings that can be conventionally controlled with passive haemostats.
  • the invention is directed to provide haemostasis to bleedings such as capillary bleeding, oozing bleeding, venous and arteriolar bleeding.
  • the invention provides haemostasis for minor bleedings that may occur on a larger surface.
  • small bleedings on a liver surface are suitably treated by the present invention.
  • the present invention is not specifically directed to closing a puncture in a wall of artery which entails strong, pulsating bleeding.
  • one aspect of the invention relates to a medical device comprising: a means for providing static mechanical pressure on a tissue, venal or arterial area; and a means for delivering an agent to the area; wherein the delivering of the agent is by means of an outlet from a hollowed member, said hollowed member having a cross-sectional area wherein the means for providing the static mechanical pressure is suitable for exerting said mechanical pressure over a surface area of at least twice that of the cross-sectional area of the hollow member.
  • a further aspect of the invention is directed to a medical device comprising: a means for providing static mechanical pressure on a tissue venal or arterial area, said means being an expansible means so as to provide said pressure on the area; and a means for delivering an agent to the area.
  • the means for delivering the agent comprises a hollowed member having an agent inlet and outlet.
  • the hollow member is defining a channel there between for containing and/or delivering said agent, as shown in Figure 1.
  • the means for providing the pressure comprises expansible means provided externally on said hollowed member (or a part thereof) and being expansible so as to provide said pressure on the area.
  • the expansible means comprises a flexible inflatable membrane, such as a balloon-type device.
  • the inflatable membrane may be of any material suitably elastic and impermeable allowing for inflation and is conventionally known in the art.
  • the inflatable membrane or balloon of the invention is intended for compression directly on the bleeding site and for fitting bleeding cavities, etc.
  • the balloon can change its shape according to the material it is made from, the amount of air or fluid that it is inflated with and the tissue on which it is applied.
  • the volume of the means can be varied according to the size of the bleeding area.
  • the expansible means provided by an inflatable membrane is expanded to provide the static mechanical pressure over a surface area of at least twice that of the cross-sectional area of the hollow member, such as at least 2.5 times, typically at least 3 times, more typically at least 3.5 times the cross- sectional area of the hollow membrane.
  • the means for providing the static mechanical pressure is typically suitable for exerting said mechanical pressure over a surface a rea of 2-50 times that of the cross-sectional area of the hollow member, such as 2.5-50 times, such as 3-50 times, such as 3.5 -50 times the cross-sectional area of the hollow member.
  • the diameter of the expanded membrane is suitable for expansion to a diameter of more than lxl cm, such as more than 1.5x1.5 cm, such as more than 2x2 cm.
  • the diameter of the expanded membrane may be from lxlcm to 40x40 cm, preferably from 1.5x1.5 cm to 30x30 cm, more preferably 2x2 cm to 20x20 cm, more typically 2x2cm to lOxlOcm, such as 5x5 cm.
  • the inflatable membrane is attached to an outer surface of the hollowed member and being in communication with an inlet provided in the end towards the agent inlet of the hollowed member.
  • the membrane is attached to an outer surface of the hollowed member.
  • the membrane is in communication with an inlet provided in the end towards the agent inlet of the hollowed member thereby and comprising a compressible chamber.
  • said compressible chamber is containing a transferable material selected from the group of gas, fluid, gel and foam or a 10 combination thereof to expand the expansible means, said chamber and expansible means together defines a fluid tight volume.
  • said expansible means being adapted to be expanded upon compression of said chamber.
  • the expansible means comprises a sheathing 15 member adapted to receive and surround at least a part of said hollowed member, the sheathing member comprising a inlet, a flexible inflatable membrane to be expanded, and a channel providing communication between the inlet and the membrane.
  • the hollowed member and sheathing member are typically substantially circular in cross-section.
  • the device of the invention typically comprises a plunger for pressing said agent through the channel and out of said outlet. It may furthermore comprise a plunger for pressing fluid, air or gas into the inflatable membrane. It may furthermore comprise a plunger for compressing the compressible chamber.
  • the inflatable membrane extends around a part of or the entire circumference of the hollowed member.
  • the membrane may be expanded by gas or liquid. Suitable gases include air, oxygen, nitrogen and helium. Any number of liquids is suitable.
  • the inflatable membrane which provides the mechanical pressure is filled with a gas or liquid at a temperature below body temperature, such as below 30°C, such as below
  • the temperature of the gas or liquid may be in the range of -180°C to +50°C, such as -100 to +50°C, typically -75 to +50°C, more typically -50 to +40°C. Temperatures below body temperature may assist in the haemostatic process. Temperatures below 0°C may also damage cellular structure which may also assist in the
  • the hollow member has a length of less than 80 cm, preferably less than 60 cm, such as less than 50 cm, such as less than 40 cm.
  • the hollowed member has a length of more than 5 cm, such as more than 10 cm, 20 cm, 25 cm and 30cm.
  • the hollow member has a length of 5 to 60 cm, preferably 10 to 55 cm, more preferably 20 to 50 cm, most preferably 30 to 45 cm, such as 40 cm.
  • the hollowed member's length is suitably dimensioned to 5 to 20 cm, such as 5 to 15 cm, such as 5 to 10 cm.
  • the length of the hollow member may be varied in length depending on its intended use and the age and gender of the patient.
  • the hollowed member or the sheathing member has an outer diameter of more than 0.5 mm, preferably more than 2.5 mm, 5 mm, 7.5mm and l O mm. In another embodiment the hollowed member or the sheathing member has an outer diameter of less than 20 mm, preferably less than 17.5 mm, 15 mm, 10 mm and 7.5 mm. In an alternative embodiment the sheathing member's length is suitably dimensioned 0.5 to 20 mm, preferably 5 to 15 mm, such as 10 mm.
  • the hollowed member suitably has an inner diameter of less than 18 mm, preferably less than 14 mm, more preferably less than 10 mm, such as 8 mm.
  • the hollowed member may have an inner diameter of 0.5 to 18 mm, preferably 2 to 14 mm, most preferable 6 to 10 mm, such as 8 mm.
  • the expansible means may be expansible symmetrically or asymmetrically in relation to the longitudinal axis of the hollowed member or sheathing member.
  • the hollowed member may be made of any array of materials such as glass or plastic, polypropylene or polyethylene.
  • the hollow member may be made of any material, which when provid ing an inner diameter of 1-15 mm and an outer diameter of 2-20 mm is substantially rigid but with some degree of flexability along the axis of the hollow member. In a preferred embodiment the hollowed member is substantially rigid.
  • the sheathing member and membrane is made of rubber or plastic, such as polypropylene based and/or polyethylene based.
  • the medical device adapted to be used in connection with an endoscope or a laparoscopic procedure.
  • the medical device, or part of the medical device and/or the hollow member is transferred to the site of action through the trocar.
  • the medical device may comprise an agent, typically a haemostatic agent.
  • the haemostatic may be selected from the group consisting of a passive haemostat, an active haemostat, an antiadhesive agent and a combination thereof.
  • the haemostatic agent may further comprise other agents to assist in its movement through the hollow membra ne, as well as stabilisers, colouring agents, and tackifiers.
  • the agent comprises a haemostatic agent and a tackifying agent.
  • the agent comprises an antiadhesive agent and a tackifying agent.
  • the agent may comprise a haemostat and/or an antiadhesive agent.
  • the haemostatic agent is an antifibrinolytic agent, wherein the antifibrinolytic agent is selected from the group of consisting of tranexamic acid, a protinin or aminocaproic acid or a combination thereof.
  • the haemostatic agent is an active haemostatic agent.
  • Suitable active haemostatic agents many be selected from the group of consisting of fibrin, thrombin, coagulation factors or a combination thereof.
  • the agent is in powder form. In a more typical embodiment, the agent is a powdered haemostatic agent. In a preferred embodiment the agent comprises a polymer selected from the group consisting of gelatine, collagen, cellulose, chitosa n or a combination thereof, more preferably selected from gelatine or collagen.
  • the haemostatic agent is collagen powder or collagen- derived powder.
  • said collagen or collagen-derived powder is gelatine.
  • the gelatine may be derived from an animal or are made synthetically, such as recomb inantly.
  • the gelatine originates from porcine but may originate from other mamm als.
  • the powder is preferably sterile.
  • the agent is in a mixture with a liquid.
  • the liquid may be water or a physiologically balanced solution, such as a saline solution typically at a pH of 5-8.5, more typically 5.5-8, such as 6-8.
  • the mixture is a combination of a liquid active haemostatic agent and a powdered passive haemostatic agent.
  • the mixture is a combination of thrombin and gelatine or thrombin and collagen.
  • the agent is a mixture of gelatine or collagen in saline or water.
  • the haemostatic agent is a processed gelatine or collagen-derived powder.
  • said agent may be processed in such a manner so as to expand in particular after or upon application by the medical device.
  • the increase in size may commence while in the medical device itself, or upon or after application.
  • the processed agent will influences the structure of the agent, such as the microstructure.
  • the processed agent may allow for a change in the particle size of the flake-like gelatine powder. .
  • the processing of the agent will result in a modification of the flake-like structure of the powder.
  • the processed agent increases in particle size, such as the size of a flake-like gelatine powder, upon or after application by the medical device.
  • the processed agent will result in an improved porosity of the gelatine powder.
  • the increase in particle size of the agent may create a compression on the application site, thereby promoting haemostatis at the site of bleeding or site of application
  • the agent with in the device can be processed such that the agent is compressed while within the medical device and expands upon use by means of decompression upon delivery of the agent.
  • the expansion causes a compression on the application site, thereby promoting haemostatis at the site of bleeding or application site.
  • the effect of the processed agent is such that its volume increases after application.
  • the increase of the volume may occur due to absorption of fluids.
  • the agent is in powder form
  • typically 95% of the powder is less than 1000 microns in size, preferably such that 90% of the second volume is less than approximately 700 ⁇ m.
  • 50% volume is less than approximately 350 ⁇ m.
  • the agent is in powder form in a mixture with a liquid
  • typically 95% of the powder is less than 1000 microns in size, preferably such that 90% of the second volume is less than approximately 700 ⁇ m.
  • 50% volume is less than approximately 350 ⁇ m.
  • the mean particle size of the powder haemostat is such that the powder possesses sufficient flowability properties.
  • the mean particle size is in the range of 10-250 ⁇ m, such as in the range of 20-250 ⁇ m.
  • the mean particles size is in the range of 20-200 ⁇ m, such as in the range of 30-180 ⁇ m, e.g. in the range of 40- 175 ⁇ m, more preferably in the range of 50-150 ⁇ m, such as in the range of 55-125 ⁇ m, e.g. in the range of 60-100 ⁇ m or in the range of 70-90 ⁇ m.
  • the term "mean particle size" is defined with reference to the examples provided herein, i.e. the mean particle size is based on laser diffraction measurements.
  • the particles preferably have a particle size distribution so that 90% of the particles have a particle size below 200 ⁇ m, such as below 190 ⁇ m, e.g. below 180 ⁇ m, more preferably below 170 ⁇ m.
  • the particle size distribution is preferably so that 90% of the particles have a particle size above 5 ⁇ m, such as above 10 ⁇ m, e.g. above 15 ⁇ m.
  • the powder may be prepared from a gelatine sponge cut into pieces that fit into a mill and that will be bulk packaged into sterilization bags and placed in an oven (dry heat), for hardening for three hours.
  • the gelatine plates raw material are typically manually fed into a rotor knife mill with a sieve for final grinding.
  • the particle size is preferably such that not more than 5% (w/w) is retained on a 1 mm mesh.
  • the resulting powder of said preparation is characterised by their flakelike shape.
  • the flakelike shape of said gelatine powder differ that of gelatine powder produced by a simple milling process leaving out the hardening procedure.
  • the flakelike shape of the gelatine powder is essential for the efficiency of the passive haemostate.
  • the flakelike shape of the gelatine powder is essential for the flowability of the gelatine powder.
  • the agent preferably gelatine must have a suitable density for the agent to be delivered unproblematically through the hollowed member.
  • density refers to "apparent density” as defined in European Pharmacopoeia.
  • the agent preferably gelatine, have an apparent density of 0.05-1.5 g/ml, such as 0.06-1 g/ml, typically from 0.075-1 g/ml.
  • the gelatine or collagen powder preferably has a poured density in the range of 0.05-0.3 g/ml, such as in the range of 0.O6-0.25 g/ml, e.g. in the range of 0.07-0.20 g/ml, more preferably in the range of 0.075-0.15 g/ml.
  • the gelatine or collagen powder preferably has a tapped density in the range of 0.075-0.4 g/ml, such as in the range of 0.1-0.3 g/ml, e.g. in the range of 0.125- 0.25 g/ml, more preferably in the range of 0.15-0.25 g/ml.
  • the agent comprises a powder suspended in water, saline, a solvated active haemostat, a suspended active haemostat or a combination thereof.
  • said haemostat consists of gelatine powder suspended in saline.
  • the suspension must be diluted sufficiently for the mixture to pass the hollowed member unproblematically. On the other hand the mixture must not be diluted too much as this might compromise the haemostatic effect.
  • the degree of dilution must be prepared in such a manner that the flowability of the mixture is suitable unhindered passage through the hollow member. The degree of dilution suitable depends on the flowability and of the particle size of the dried powder.
  • said gelatine being gelatine powder having a specific surface area is preferably at least 0.15 m 2 /g (e.g. 0.15-3.00 m 2 /g or 0.25-2.00 m 2 /g) such as at least 0.35 m 2 /g (e.g. 0.35-3.00 m 2 /g or 0.35-2.00 m 2 /g), more preferably at least 0.50 m 2 /g (e.g. 0.50-3.00 m 2 /g or 0.50-2.00 m 2 /g), such as at least 0.75 m 2 /g (e.g. 0.75-3.00 m 2 /g or 0.75-2.00 m 2 /g).
  • the specific surface area is at least 0.90 m 2 /g (e.g. 0.90-3.00 m 2 /g or 0.90- 2.00 m 2 /g), such as at least 1.00 m 2 /g (e.g. 1.00-3.00 m 2 /g or 1.00 to 2.00 m 2 /g).
  • the specific surface area may be at least 1.25 m /g (e.g. 1.25-3.00 m 2 /g or 1.25-2.00 m 2 /g), such as at least 1.50 m 2 /g (e.g. 1.50-3 m 2 /g or 1.50-2.00 m 2 /g).
  • the specific surface is conveniently determined by gas adsorption (BET).
  • the surface area of the powder may have an influence on the efficiency of the gelatine or collagen powder as a haemostatic agent as well as of being an antiadhesive agent.
  • the surface area of the powder has influence on the degree of diluting when preparing the mixture; as is known to the person skilled in the art, the larger the surface area, the higher the ratio of liquid needed.
  • the medical device of the invention further comprising iii) the agent.
  • the agent is typically contained inside the hollow member.
  • the agent may be comprised in a delivery system.
  • the agent may be delivered through a syringe system or any other suitable delivery device.
  • a further aspect of the invention is directed to a kit comprising the medical device, the agent, and a delivery system, such as a syringe with plunger.
  • the agent may be comprised within the delivery system or in a separate container.
  • the kit may comprise the medical device and a syringe with plunger.
  • a further aspect of invention relates a particularly interesting delivery system, said device being in the form of a pen-like device.
  • This pen-like device is a device suitable for pressurised delivery of an agent wherein the delivery is through an outlet of a hollowed member upon compression of a bow engaged with a serrated edge portion of a serrated piston located within the hollowed membrane, so as to propel the piston in the direction of the outlet, said engagement being through an aperture in said hollowed tubular membrane. Compression of the engaged bow propels the piston in the direction of the outlet by a distance defined by the radius of the bow so as to deliver the agent. Release of the compression allows for the bow to return to its curved position of higher potential energy and to re-engage with a second serrated edge portion of the piston, said second serrated edge portion being distally positioned on the piston from the outlet.
  • the delivery is made in finite volumes defined by the radius of the bow in concert with the spacing of the serrated edges.
  • the degree of compression can be so as to project the serrated piston by a distance of 1-4 serrations, such as 1, 2, 3, or 4 preferably 1, 2 and 3 serrations, more preferably 1 and 2 serrations.
  • full compression propels the piston a distance of 2 serrations and slight compression propels the piston by a distance of 1 serration.
  • the bow In order for the bow to return to its position of maximal potential energy, it's resting position, it must re-engaged with a serration distally located on the piston from the outlet.
  • the hollowed member may be a hollowed tubular member with an inner diameter appropriate and suitable for the agent to be delivered.
  • the agent may be in an array of forms such as in the form of a liquid, solid granules, powder, paste, suspension or emulsion.
  • the radius of the bow is such that compression of its arch results in the projection of the serrated piston so as to deliver a volu me of 0.05 to 2 mL per full compression, typically 0.075 to 1 mL, more typically 0.1 to 0.5 mL, such as 0.1, 0.2, 0.3, 0.4 and 0.5 mL.
  • the present inventors have found that the delivery is of a hig h pressure compared to conventional devices, and suitable for delivery of a powdered agent at a pressure of 50- 200 N, such as 75-200 N, typically 100-180 N.
  • the bow of the pen-like device is typically located along the longitudinal axis of the hollow member so as to render the device easy to hold and use at the same time, such as by compression by the thumb.
  • Figure 2 depicts an illustrative example of the pen-like device.
  • a further aspect of the invention is directed to a kit comprising the medical device, the agent, and a delivery system, such as the pen-like delivery device.
  • the agent may be comprised within the delivery system or in a separate container.
  • the kit may comprise the medical device and the pen-like delivery device.
  • a further aspect of the invention is directed to a method of providing haemostasis comprising the use of a medical device as defined herein.
  • a further aspect of the invention is directed to a method of providing haemostasis comprising the use of the kit as defined herein.
  • the invention provides for a method of providing haemostasis comprising providing mechanical pressure and simultaneously or sequentially delivering a haemostatic agent, wherein the delivering of the agent is by means of an outlet from a hollowed member, said hollowed member having a cross-sectional area wherein the mechanical pressure is applied over a surface area of at least twice that of the cross-sectional area of the hollowed member.
  • the invention alternatively provides for method of providing haemostasis comprising providing mechanical pressure and simultaneously or sequentially delivering a haemostatic agent, said mechanical pressure applied by an expansible means.
  • the invention further provides for method of providing haemostasis to a tissue comprising providing mechanical pressure and simultaneously or sequentially delivering a haemostatic agent.
  • the invention is further defined by the present Examples in a non-limiting fashion.
  • Example 1 Product and Preparation Gelatine powder was obtained from milling sheets of Surgifoam ® sponge under a controlled process to produce a product meeting the following specification : 5
  • the powder is a porcine gelatin based powder, off white in colour.
  • 10% volume is less than approximately 90 ⁇ m; 50% volume is less than approximately 350 ⁇ m; 10 90% volume is less than approximately 700 ⁇ m; as determined by laser diffraction.
  • the milled product is collected under slight negative pressure to avoid particulate emission in the area and filled into a primary container, such as by using a hopper and scoop filling 15 operation or by using pharmaceutical cGMP standard auger filling equipment.
  • the haemostatic effect of a preliminary model of the product was tested in a porcine model.
  • An open laparoscopy was performed in euthanized pigs. Once the gall bladder had 20 been removed oozing bleeding from the liver bed could be observed.
  • a gelatin powder was mixed with saline and applied on the bleeding site through a 25 cm long applicator where after mechanical pressure was applied by inflating the balloon. After two minutes the inflated balloon was removed and it was found that the oozing bleedings had stopped.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Surgical Instruments (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

La présente invention concerne un dispositif médical permettant l'hémostase à l'aide d'un cathéter expansible exerçant une pression mécanique et garantissant l'hémostase. L'invention permet aux chirurgiens de procéder à l'hémostase en cas d'hémorragie généralisée sur une zone de surface étendue ou des zones tissulaires localisées.
PCT/DK2005/000064 2004-01-30 2005-01-28 Dispositif hemostatique WO2005072623A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54000804P 2004-01-30 2004-01-30
US60/540,008 2004-01-30
US54986404P 2004-03-04 2004-03-04
US60/549,864 2004-03-04

Publications (1)

Publication Number Publication Date
WO2005072623A1 true WO2005072623A1 (fr) 2005-08-11

Family

ID=34830498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000064 WO2005072623A1 (fr) 2004-01-30 2005-01-28 Dispositif hemostatique

Country Status (2)

Country Link
AR (1) AR054636A1 (fr)
WO (1) WO2005072623A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257225B1 (fr) * 2008-03-17 2017-04-19 Ethicon, Inc. Instruments d'application utilisés pour installer, déployer et tamponner des hémostats

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584959A2 (fr) 1992-07-27 1994-03-02 Symbiosis Corporation Système pour la delivrance endoscopique d'un agent hémostatique
US5419765A (en) * 1990-12-27 1995-05-30 Novoste Corporation Wound treating device and method for treating wounds
US5443481A (en) 1992-07-27 1995-08-22 Lee; Benjamin I. Methods and device for percutaneous sealing of arterial puncture sites
US5725551A (en) * 1993-07-26 1998-03-10 Myers; Gene Method and apparatus for arteriotomy closure
US5728134A (en) * 1996-09-17 1998-03-17 Barak; Shlomo Method and apparatus for hemostasis
WO2000018301A1 (fr) 1998-09-25 2000-04-06 Biointerventional Corporation Melange et systeme de scellement biologique utilise pour l'occlusion percutanee de sites de ponction et de conduits dans le corps humain, et procede associe
US6368300B1 (en) 1995-01-18 2002-04-09 C. R. Bard, Inc. Apparatus for applying a hemostatic agent onto a tissue
WO2003055531A2 (fr) 2001-12-21 2003-07-10 Ferrosan A/S Kit hemostatique, procede de preparation d'agent hemostatique et procede favorisant l'hemostase

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5419765A (en) * 1990-12-27 1995-05-30 Novoste Corporation Wound treating device and method for treating wounds
EP0584959A2 (fr) 1992-07-27 1994-03-02 Symbiosis Corporation Système pour la delivrance endoscopique d'un agent hémostatique
US5443481A (en) 1992-07-27 1995-08-22 Lee; Benjamin I. Methods and device for percutaneous sealing of arterial puncture sites
US5725551A (en) * 1993-07-26 1998-03-10 Myers; Gene Method and apparatus for arteriotomy closure
US6368300B1 (en) 1995-01-18 2002-04-09 C. R. Bard, Inc. Apparatus for applying a hemostatic agent onto a tissue
US5728134A (en) * 1996-09-17 1998-03-17 Barak; Shlomo Method and apparatus for hemostasis
WO2000018301A1 (fr) 1998-09-25 2000-04-06 Biointerventional Corporation Melange et systeme de scellement biologique utilise pour l'occlusion percutanee de sites de ponction et de conduits dans le corps humain, et procede associe
WO2003055531A2 (fr) 2001-12-21 2003-07-10 Ferrosan A/S Kit hemostatique, procede de preparation d'agent hemostatique et procede favorisant l'hemostase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257225B1 (fr) * 2008-03-17 2017-04-19 Ethicon, Inc. Instruments d'application utilisés pour installer, déployer et tamponner des hémostats

Also Published As

Publication number Publication date
AR054636A1 (es) 2007-07-11

Similar Documents

Publication Publication Date Title
US5989215A (en) Fibrin delivery device and method for forming fibrin on a surface
US5951583A (en) Thrombin and collagen procoagulant and process for making the same
EP2521538B1 (fr) Produit d'obturation à base de fibrine en poudre sèche
AU2017203958B2 (en) Hemostatic device
WO2018113147A1 (fr) Éponge de gel sec d'un hydrogel polymère super-hydroabsorbant, procédé de préparation s'y rapportant et utilisation associée
EP0917444A1 (fr) Dispositif distributeur de fibrine et procede de formation de fibrine sur une surface
AU2002307809A1 (en) A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same
WO2002058750A2 (fr) Suspension à base de fibrinogène, thrombine et alcool et mode d'élaboration, procédés d'enrobage d'un support d'une telle suspension et de séchage de l'enrobage du support, et éponge enduite de collagène
WO2004064878A1 (fr) Materiaux hemostatiques
KR101786786B1 (ko) 개선된 피브린 밀봉 방법
CA2896760A1 (fr) Dispositif et procede d'application d'une composition fluide durcissable sur une partie d'un organe corporel
CN116570757A (zh) 一种基于超电荷蛋白的双组分原位粘合剂及其制备方法和用途
WO2005072623A1 (fr) Dispositif hemostatique
Cortes et al. Pre-emptive placement of a presealant for amniotic access
AU2012347804B8 (en) Hemostatic device
JP2012529976A (ja) 止血性材料および送達デバイス

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase